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Abstract
Background: Postpartum haemorrhage remains a major cause of maternal mortality and morbidity worldwide. Active
management of the third stage of labour reduces the risk of postpartum haemorrhage. Oxytocin and oxytocin/ergometrine
are commonly used in the UK, with oxytocin/ergometrine being more effective at preventing moderate, but not severe,
blood loss. Many guidelines specifically recommend using oxytocin for all vaginal births, as it is associated with fewer
adverse events. However, a survey conducted by the Southmead Hospital Maternity Research Team revealed that 71.4% of
UK obstetric units still routinely use oxytocin/ergometrine. Carbetocin is a newer medication that may be as effective but
has fewer side effects. No studies have directly compared all three medications.
Methods: The IMox study aims to determine the most effective, acceptable and cost-effective drug for primary prevention of
postpartum haemorrhage following vaginal birth. The IMox study is a prospective, multi-centre, double-blind, randomised trial
directly comparing oxytocin, oxytocin/ergometrine and carbetocin given intramuscularly for the prevention of postpartum
haemorrhage in the third stage of labour. The primary effectiveness outcome is the use of an additional uterotonic drug.
Secondary effectiveness outcomes reflect maternal morbidity and mortality within the immediate postpartum period.
Participant questionnaires and subjective reporting of side effects will be used to evaluate maternal acceptability. Maternal
quality of life utilities will be collected antenatally, and on days 1 and 14 after birth to enable a cost-effectiveness assessment
of each studied drug.
Participants will be pregnant women planning a vaginal birth in six hospitals in England. Participants will be approached
and invited to provide consent to participate from 20weeks gestation until in established labour. A complete sample of
5712 participants (1904 per arm) providing data for the primary outcome will allow for a robust determination of efficacy
between all three study drugs. Data will be collected until participants are discharged from the hospital and on postnatal
days 1 and 14 regardless of location. All analyses will be on a modified intention-to-treat basis, and additionally repeated
on a per protocol basis. Data collection commenced in Feburary 2015 and was completed in August 2018.
(Continued on next page)
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Discussion: This study is the first to directly compare oxytocin, oxytocin/ergometrine and carbetocin in the same population
for the prevention of postpartum haemorrhage following vaginal birth. Furthermore, this study will be the first to directly
compute health economic outcomes from such a three-way comparison. This study is limited to using short-term outcomes,
and so will not provide evidence for important outcomes such as long-term maternal psychological well-being and time to
next conception.
Trial registration: ClinicalTrials.gov, NCT02216383. Registered on 18 August 2014. EudraCT, 2014-001948-37. Registered on 23
September 2014. ISRCTN, ISRCTN10232550. Retrospectively registered on 6 March 2018).
Keywords: Postpartum haemorrhage, Prevention, Primary, Oxytocin, Oxytocin/ergometrine, Carbetocin
Background
Primary postpartum haemorrhage (PPH), defined as a
loss of ≥500 ml of blood from the genital tract within 24
h of delivery, remains a major cause of maternal morbid-
ity and mortality worldwide, accounting for more than a
quarter of all global maternal deaths [1]. In addition to
the significant risk of immediate adverse events, PPH is
significantly associated with long-term physical and psy-
chological morbidity [2]. The need for treatments such
as additional uterotonic drugs, blood transfusion, opera-
tive procedures including hysterectomy and prolonged
hospital stay affect not just the woman experiencing the
haemorrhage, but also her family and the health service,
which incurs additional costs. Approximately 70% of
PPHs are caused by inadequate uterine contraction after
delivery of the placenta (uterine atony) [3]. Prophylactic
administration of a uterotonic drug in the third stage of
labour, together with early cord clamping and con-
trolled cord traction, reduces the incidence of primary
PPH by 66%, when compared with physiological man-
agement [4]. The majority of women who experience
PPH have no risk factors [5], and it is therefore recom-
mended that this active management of the third stage
of labour (AMTSL) is routinely offered to all labouring
women [5–7].
There are several prophylactic uterotonic agents avail-
able for use, including oxytocin, oxytocin/ergometrine
and carbetocin. Oxytocin and oxytocin/ergometrine are
commonly used for vaginal deliveries, while carbetocin
is presently only licensed for use at caesarean section.
Carbetocin is a synthetic analogue of oxytocin which
provides a longer duration of action than oxytocin
(half-life 85–100 min versus 3–4 min) [8].
Although there are no trials directly comparing all
three of oxytocin, oxytocin/ergometrine and carbetocin
for prophylaxis of PPH after vaginal birth, a Cochrane
network meta-analysis (NMA) on this subject was pub-
lished in 2018 [9]. This NMA demonstrated rates for
PPH ≥ 500 ml of 10.5%, 7.2% and 7.6% for oxytocin, oxy-
tocin/ergometrine and carbetocin respectively, and rates
of PPH ≥ 1000ml of 3.6%, 2.8% and 2.5% respectively.
Additionally, the NMA demonstrated higher rates of
adverse outcomes following the use of oxytocin/ergo-
metrine than both oxytocin and carbetocin (hyperten-
sion 1.2%, 0.7% and 0.6% respectively and vomiting
1.9%, 0.5% and 0.6% respectively).
Since publication of this NMA, the results of a large
multi-national non-inferiority clinical trial in 30,000
women of oxytocin versus carbetocin for prophylaxis of
PPH have been published by Widmer et al. [10]. This
trial demonstrated non-inferiority of carbetocin relative
to oxytocin for the prevention of PPH ≥ 500 ml (relative
risk (RR) 1.01; 95% confidence interval (CI), 0.95 to
1.06). The use of additional uterotonic agents and inter-
ventions to stop bleeding and the occurrence of adverse
effects were not shown to differ significantly between
the two groups.
The trial was not sufficiently powered to demonstrate
non-inferiority for PPH ≥ 1000ml.
Taken together, these recent results suggest that carbe-
tocin may be as effective as (or potentially more effective
than) oxytocin, and associated with fewer adverse events
than oxytocin/ergometrine.
Current national and international guidelines advocate
the use of intramuscular oxytocin as the prophylactic
uterotonic agent of choice in the third stage of labour
for low-risk women delivering vaginally [5–7, 11]. How-
ever, an unpublished telephone survey of all obstetric
units in the UK in October 2013 conducted by our team
found that 71% of units still use oxytocin/ergometrine
for normotensive women having a vaginal birth despite
these recommendations. Many units volunteered that
their local departmental audits had shown increases in
their PPH rates following a switch to oxytocin in line
with national guidance, and that they therefore reverted
to oxytocin/ergometrine despite its known side effects.
The care being provided to women on a national scale is
clearly suboptimal in this respect, which suggests that an
alternative prophylactic uterotonic agent may be needed.
Very few studies have investigated the cost-effectiveness
of carbetocin. The need for new studies investigating the
cost and cost consequences of carbetocin was highlighted
in a Cochrane review [12]. This additional information is
crucial, particularly as carbetocin is more expensive at UK
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list price (£17.64 versus £0.91 for oxytocin and £1.38
oxytocin/ergometrine), and any additional benefits or
resource use would need to be weighed against the higher
acquisition price.
While the recent Cochrane NMA and the study by
Widmer et al. add substantial weight to the case that
carbetocin may be as effective as (and potentially more
effective than) oxytocin and associated with fewer adverse
events than oxytocin/ergometrine, the resistance to bring
practice into line with current guidelines (at least within
the UK) demonstrates the need for primary direct trial
evidence for the clinical effectiveness, maternal acceptabil-
ity and cost-effectiveness of these commonly used drugs.
Methods/design
Aims
The primary study aims are to determine if:
 Carbetocin is at least as effective as oxytocin/
ergometrine
 Carbetocin is more effective than oxytocin
 Oxytocin/ergometrine is more effective than
oxytocin
The secondary study aims are to establish whether:
 Carbetocin is associated with fewer adverse events
than oxytocin/ergometrine and oxytocin
 Carbetocin is a cost-effective alternative to oxytocin/
ergometrine and oxytocin
Trial design and justification of comparisons
The IMox study is a multi-centre, double-blinded,
randomised trial to compare oxytocin, oxytocin/ergo-
metrine and carbetocin given intramuscularly after vagi-
nal birth for prevention of primary PPH. Drugs will be
compared in terms of clinical effectiveness, maternal
acceptability and cost. Participants will be randomised to
parallel arms in a 1:1:1 ratio. A Consolidated Standards
of Reporting Trials (CONSORT) diagram of the IMox
study is given in Fig. 1.
Fig. 1 CONSORT diagram of the IMox study
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A non-inferiority comparison between carbetocin
and oxytocin/ergometrine has been chosen, as oxyto-
cin/ergometrine is associated with greater maternal
side effects. Should carbetocin be non-inferior to
oxytocin/ergometrine for the primary outcome and be
associated with fewer maternal side effects, it is likely
to be superior as a prophylactic uterotonic drug.
Superiority comparisons will be drawn between oxyto-
cin/ergometrine and oxytocin as well as carbetocin
and oxytocin.
Participants
Women aged ≥ 18 years with a live singleton preg-
nancy who have a vaginal birth (spontaneous or
instrumentally assisted) at any gestation are eligible
to participate. The exclusion criteria are as follows:
women with known or suspected antenatal hyperten-
sive disorders, intrapartum hypertension (defined as
a single systolic blood pressure ≥ 160 mmHg, or two
consecutive blood pressures of ≥ 140 mmHg systolic
or ≥ 90 mmHg diastolic taken 30 min apart), antepar-
tum haemorrhage of ≥ 50 ml, confirmed maternal
coagulation disorder or intrauterine fetal death in
the current pregnancy, women who would decline
blood products, women with severe peripheral vascu-
lar, cardiac or hepatic disease, women with epilepsy,
women with an allergy or sensitivity to any of the
ingredients in any of the study drugs, women unable
to read and write English sufficiently as to preclude
completion of maternal questionnaires and caesarean
section.
Setting
The sites will be six maternity units across the south-
west and centre of England. These include teaching
hospitals and district general hospitals.
Intervention
A single dose intramuscular injection of the study
drug (10 IU oxytocin or 500 μg/5 IU oxytocin/ergo-
metrine or 100 μg carbetocin) will be given immedi-
ately after the vaginal birth of the baby and clamping
of the umbilical cord.
Outcomes
Primary clinical outcome
The primary outcome measure is the proportion of
women requiring additional uterotonic drugs after
administration of the study drug. This primary out-
come measure was chosen over severity of PPH for
the following reasons: estimation of obstetric blood
loss is known to be inaccurate regardless of the mode
of estimation [13, 14]; vaginal or cervical tears con-
tribute to the incidence and severity of PPH without
any role of uterine atony; lastly the administration of
several additional uterotonic drugs may in some cases
be used to successfully avoid blood loss of ≥ 500 ml.
This would not be captured with a primary outcome
of PPH incidence, which would not account for the
clinically important (and costly) administration of
additional uterotonics.
Secondary outcomes
Secondary effectiveness outcomes Secondary effective-
ness outcomes will include the number and type of
additional uterotonic drugs required, weighed estimated
blood loss at delivery (in millilitres), transfusion of blood
products (number of units and type of blood product),
use of other surgical/mechanical measures to treat PPH
(need for manual removal of the placenta/examination
under anaesthetic/intrauterine balloon/uterine compres-
sion suture/interventional radiology/hysterectomy) and
maternal blood pressure at 1 and 2 h postnatal.
Maternal acceptability outcomes Patient-reported out-
comes will include symptoms of nausea, vomiting, head-
ache, dizziness or abdominal pain.
Other data collected and cost outcomes Other data
collected to allow for adjustment of results and analysis
are maternal age, body mass index (BMI), ethnicity,
history of past PPH, gravity, parity, onset of labour
(spontaneous or induced), length of first, second and
third stages of labour (in minutes), intrapartum pyrexia,
weight of baby, mode of birth, gestation at birth, length
of inpatient stay, use of oxytocin to induce or augment
labour, use of terbutaline sulphate during labour, use of
tranexamic acid, length of time spent in recovery
(minutes), length of time between delivery and discharge
from the labour ward (minutes), total length of the post-
natal hospital stay (minutes) and maternal health-related
quality of life (measured with the EQ-5D-5 L antenatally,
day 1 and day 14 postpartum).
Patient and public involvement
Patients and the public were not involved with the de-
sign, planning or delivery of the IMox study. Results of
the study will not be directly communicated to study
participants due to the considerable burden of doing
so. However, summaries of results will be distributed
using existing networks of patients (such as Maternity
Voices, a maternity advocacy group within the South
West of England).
Recruitment
Eligible women will be approached by members of the
research team in the study sites from 20 weeks gestation.
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Each woman will be provided with a Participant Infor-
mation Leaflet (PIL) and invited to provide her informed
consent. No trial procedures will take place before
informed consent is received.
Blinding, randomisation and allocation
Participants, members of the research team and clinical
staff caring for the woman will be blinded to the allocated
uterotonic. Study drugs will be manufactured in identical
1-ml vials by an independent pharmaceutical unit and
block-randomised according to a computer-generated
randomisation code. When vaginal birth is imminent, the
next consecutively numbered study drug will be taken
from the labour ward refrigerator and administered.
Unblinding will be possible in emergency clinical situa-
tions where knowledge of the administered drug would
change the patient’s management via a 24-h telephone
service.
Data collection methods
Primary and secondary outcome data will be collected
before the participant is discharged from the labour ward.
Maternal quality of life data will be collected in person
antenatally prior to the onset of labour and on day 1 post-
natally during an interview with a member of the study
team. Maternal quality of life at 2 weeks postpartum will be
collected via a telephone interview with the participant. If
participants are not contactable by telephone, they will be
sent a data collection form with a stamped, addressed enve-
lope. A participant timeline is shown in Fig. 2. All data will
be entered into an online, password protected Microsoft
Access database (Microsoft Corporation, Redmond, Wash-
ington, USA) by members of the research team. The struc-
ture of the IMox study is shown in (Fig. 3).
Sample size
The sample size selected for use in this study is 5712
participants returning data for the primary outcome.
This sample size is large enough to cover all three com-
parisons. A drop-out rate of less than 0.5% between ran-
domisation (birth imminent) and administration of drug
is anticipated; therefore, the sample size has not been
inflated.
We are investigating whether carbetocin is at least as
effective as oxytocin/ergometrine and more effective
than oxytocin, based on a primary outcome measure of
the need for additional uterotonic drugs. Limited previ-
ous research indicates that carbetocin may be more
effective than oxytocin/ergometrine at preventing PPH
and is associated with significantly fewer side effects.
Therefore, if carbetocin is robustly shown to be non-in-
ferior to oxytocin/ergometrine for the primary outcome
and is associated with fewer maternal side effects, it
would be more appropriate for use as a prophylactic
uterotonic drug.
Comparisons made will therefore be:
 Superiority comparison between oxytocin/
ergometrine and oxytocin
 Superiority comparison between carbetocin and
oxytocin
 Non-inferiority comparison between carbetocin and
oxytocin/ergometrine
The study will be powered in accordance with Euro-
pean Medicines Agency guidelines and with caution
exercised on the available historical data.
Broadly pooled weighted mean prevalence (weighted
for study size) data on the need for additional utero-
tonic drugs, from the published literature comparing
intramuscular uterotonics for vaginal deliveries, are
shown in Table 1. Therefore, the differences between
drugs equate to approximately 4 points.
Superiority comparisons
To identify a 4-point difference (equivalent to a 20%
reduction (15/19 = 0.8), which is clinically significant)
between the current nationally recommended drug
(oxytocin) and the current most commonly used drug
(oxytocin/ergometrine), a sample size of 1904 per arm
would provide at least 88% power for this comparison
with an α of 0.05. The comparison would have a power
of 80% for a Bonferroni-corrected level of nominal sig-
nificance of α = 0.0167.
To identify an 8-point difference (equivalent to a 40%
reduction (11/19 = 0.6), which is clinically significant)
between the current nationally recommended drug
(oxytocin) and the new alternative (carbetocin), the pro-
posed sample size of 1904 per arm would have at least
99% power for this comparison either using an α of 0.05
(two-sided) or with a Bonferroni-corrected α of 0.0167.
Non-inferiority comparison
Non-inferiority is assessed using a two-sided CI for the
difference in proportions, and significance declared
should the CI lie entirely on the correct side of the
non-inferiority margin. For a two-sided 95% CI, a sample
size of 1904 per arm has 95% power for a non-inferiority
margin of 1% using the estimated prevalence data. A
Bonferroni-adjusted approach, using a two-sided 98% CI
would have a power of 88% under the same scenario.
Based on the above, and in acknowledgement that the
historic prevalence data may be not be precise, the trial
will proceed on a target sample size of n = 1904 per arm.
In accordance with the European Medicines Agency
Guideline on Multiplicity Issues in Clinical Trials [15], an
α = 0.05 will be used to determine statistical significance
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for all three contrasts, and additionally a threshold of α =
0.0167 (i.e. Bonferroni-corrected levels of significance) will
be used for definitive statistical evidence.
Data analysis: drug efficacy and side effects experienced
by participants
The statistical analysis of the present study is per-
formed in accordance with the principles stated in the
Consensus Guideline E9 (Statistical Principles for Clin-
ical Trials) of the International Conference on Harmon-
isation (ICH) [16], the guidelines in the CONSORT
statement for randomised trials [17], the European
Medicines Agency Guideline on Multiplicity Issues in
Clinical Trials [15] and the European Medicines
Agency Guideline on the Choice of the Non-Inferiority
Margin [18].
Fig. 2 Participant timeline for the IMox study
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A full statistical analysis plan detailing all preplanned
analyses and the methods of analysis will be finalised
prior to consenting the last participant. Analyses will be
performed on a modified intention-to-treat basis and
additionally repeated on a per protocol basis. Analysis of
the primary outcome variable and additional secondary
analyses, subset analyses and subgroup analyses will be
described in the statistical analysis plan.
In brief, primary, secondary and safety outcome data will
be reported by randomised trial arm. Continuous variables
will be summarised using the mean and standard deviation
(or median and interquartile range if the distribution is
skewed), and categorical data will be summarised as a
number and percentage.
The primary outcome variable is the need for additional
uterotonic drugs. An omnibus test for differences in the
proportions needing (not needing) additional uterotonic
drugs will be examined using the chi-square test of
association.
The chi-square test of association for a two by two
cross-tabulation (equivalent to a test for a difference
in two binomial proportions) will be used to examine
superiority between oxytocin/ergometrine and oxyto-
cin and between carbetocin and oxytocin. These
differences will be further summarised using 95%
Wald CIs for the difference between two independent
proportions along with 95% CIs for the odds ratio and
relative risk. Statistical significance will be declared if
effects are in the anticipated direction and if the
two-sided p value is less than 0.05. Definitive statis-
tical significance will be declared if the p value is
below 0.0167 (Bonferroni-adjusted level of signifi-
cance). The non-inferiority comparison between
carbetocin and oxytocin/ergometrine will proceed
using a two-sided 95% CI for the percentage in need
of additional uterotonic drugs. Non-inferiority will be
declared if this interval excludes the non-inferiority
margin.
Multivariable logistic regression for the primary
outcome variable will also be used to adjust for
known PPH risk factors: previous PPH, Asian ethni-
city, obesity (BMI ≥ 35), induction of labour, opera-
tive vaginal birth, prolonged labour (≥ 12 h), big baby
(≥; 4 kg), pyrexia in labour (≥ 38 °C once or ≥ 37.5 °C
twice 2 h apart) and parity [5]. We will also control
for clustering by centre by adjusting for maternity
units as fixed effects. A PPH risk factor will only be
included in the model providing missing data is less
than 20%. Multiple imputation will be used to exam-
ine sensitivity of conclusions to missing data on PPH
risk factors.
Table 1 Prevalence of primary outcome by uterotonic drug in
the published literature
Pooled prevalence:
need for subsequent
additional uterotonic
drugs
Percentage not requiring
additional uterotonic
drugs
Oxytocin 19.1% 80.9
Oxytocin/
ergometrine
15.2% 84.8
Carbetocin 11.5% 88.5%
Adapted from [12, 23]
Fig. 3 SPIRIT diagram for the IMox study
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Analyses for all secondary outcomes and subse-
quent analyses will be superiority analyses. Analyses
for secondary outcomes will comprise an omnibus
test (parametric analysis of variance (ANOVA),
Kruskal-Wallis test, chi-square test of association as
appropriate) and appropriate pairwise comparisons
between trial arms. Regression models will also be
used to adjust for PPH risk factors. These models
will be multivariable logistic regression models for
binary outcomes and multivariable linear regression
models (with appropriate transformation of the out-
come if required) for scale outcomes.
Effect sizes and their associated 95% CIs will be calcu-
lated for each pairwise comparison.
Cost-effectiveness analysis
Economic evaluation will be conducted from a National
Health Service (NHS) secondary care perspective.
Resource use will be valued using published cost data
(for example from NHS Reference Costs, the Personal
Social Services Research Unit (PSSRU) and the British
National Formulary), as well as information obtained
from each hospital’s finance department (i.e. ward costs).
EQ-5D-5 L values will be converted into UK value set
utilities using the ‘crosswalk’ methodology as per the Na-
tional Institute for Health and Care Excellence (NICE)
statement of August 2017 [19]. Quality-adjusted life
years (QALYs) will be estimated using the area under
the curve method [20]. Costs, QALYs and outcomes will
be estimated using regression, adjusting for trial arm
and stratification variables as per statistical analysis,
including baseline quality of life score for QALYs.
In a cost consequences framework, we will report,
per trial arm, all mean values for adjusted costs and
relevant outcomes with standard deviations, including
QALYs, the primary clinical outcome of need for
additional uterotonic drugs and secondary outcomes
of PPH, hypertension, vomiting and need for further
intervention in theatre. Utility will also be analysed
by level of PPH to help understand whether experien-
cing PPH leads to a lower utility postpartum, and for
how long this effect lasts.
A separate cost-effectiveness evaluation will be per-
formed, using effectiveness estimates directly observed in
the trial data (including measures of uncertainty) and data
from the utility analysis. These data will be combined to
calculate the bootstrapped adjusted incremental net mon-
etary benefit statistic and cost per QALY of the three
competing treatments, for non-dominant arms. In general,
a cost per QALY under £20,000 is considered a good use
of NHS resources, but we will also use thresholds of
£10,000 and £30,000 per QALY. We will derive
cost-effectiveness acceptability curves to illustrate the
uncertainty around the probability of the interventions be-
ing cost-effective for a range of thresholds.
Adverse events
Adverse events will be assessed and reported in line with
the policy of the Sponsor. Outcomes which do not need
reporting include those relating to the participant’s baby
(as the umbilical cord is clamped when the study drug is
given), the participant ≥ 12 h after birth (as the effects of
the study drug are not expected to last beyond this
point) and those which occur between the time of con-
sent and birth (before randomisation and study drug
administration occurs).
Monitoring
Monitoring will take place both remotely and on site.
Site visits will take place 6–8 weeks before each site
starts recruiting, 3 and 9 months into recruitment and
after recruitment has finished. Additional on-site visits
will be arranged to address any particular concerns
which arise, or if sites require additional support. Audit-
ing will take place when requested by the Sponsor.
Trial oversight
The trial will be overseen by a Trial Steering Committee
(TSC) and a Data Monitoring Committee (DMC). The
TSC will consist of an independent Chair, the Chief
Investigator and Principal Investigators from all study
sites. The TSC will meet quarterly to provide oversight
for the trial and ensure it is conducted in line with the
principles of Good Clinical Practice (GCP).
Interim safety results and primary outcome measure
were reviewed by the independent DMC after 50% of re-
cruitment had been completed. Premature termination
of the study was not recommended as emerging data (or
new literature) did not show beyond reasonable doubt
that any of the study drugs are clearly better for all
women or subgroups.
The study is sponsored by North Bristol NHS Trust.
Site-specific approvals for the conduct of the study have
been obtained as required. Changes to the protocol will
be implemented as required, incorporated into trial
registration and communicated to study sites once
secured. The Sponsor contributed to the initial study
design. Neither the Sponsor (North Bristol NHS Trust)
nor the funder (Ferring Pharmaceuticals Ltd.) will have
any role in the trial results analysis, interpretation, writ-
ing of the report or decision to submit for publication.
The Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) checklist was used when writ-
ing this manuscript [21] and is given in Additional file 1.
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Dissemination
Study results will be published within 2 years of completion
of data collection in a peer-reviewed open access journal,
and the results will be presented at local, national and inter-
national meetings. Health economics results will be pub-
lished separately within 2 years of completion of data
collection. Summaries will also be distributed using existing
networks of patients (such as Maternity Voices, a maternity
advocacy group within the South West of England). A sum-
mary of results will also be sent to all units that participated
in the study, unless they express the wish not to receive
such information. Results will be communicated to a lay
audience by social media activities of the University of Bris-
tol, North Bristol NHS Foundation Trust and the research
team. Participants will be able to register an interest in
study results by emailing the study email address.
Discussion
This is the first randomised controlled trial investigat-
ing whether carbetocin is an effective and affordable
alternative to oxytocin and oxytocin/ergometrine for
prevention of PPH after vaginal birth, and whether it
is associated with fewer side effects for new mothers.
Although this study is based in the UK, its findings
will be relevant to all healthcare settings, given the
global distribution of PPH. A potential limitation of
this study is the choice of primary outcome of require-
ment for additional uterotonics. While we believe this
is the most robust way to compare the real-world clin-
ical efficacy of the studied drugs (due to the wide vari-
ations reported between observers of estimated blood
loss), we acknowledge that this means our study is
unlikely to be powered to determine significant differ-
ences in estimated blood loss between the studied
drugs, the historically more commonly reported pri-
mary outcome. This does not however prevent the
data gathered on estimated blood loss from being
utilised in future meta-analyses of studies.
A core outcome set for trials examining primary pre-
vention of PPH was published by a multinational Delphi
consensus group after the commencement of the IMox
study [22]. We acknowledge that this study does not in-
clude all of these outcomes. The IMox study included
blood loss, maternal death, use of additional uterotonics,
blood transfusion, adverse effects and transfer for higher
level of care. It partially included acceptability and satis-
faction with the intervention as well as women’s sense of
well-being. It did not include breastfeeding.
This study does not use stratified randomisation to bal-
ance PPH risk factors across treatment arms. Doing so
would have made randomisation, at the time when birth
becomes imminent, logistically more difficult. The large
sample size will go some way to aid balance across the
arms, as will adjustment for these variables at the time of
statistical analysis.
As one drug (oxytocin/ergometrine) is significantly more
associated with visible side effects (nausea and vomiting)
than the other studied drugs, there is potential here for
practitioners to (correctly or incorrectly) impute what a
participant may have received from the effect on that par-
ticipant, and alter their practice accordingly. It is not pos-
sible to quantify this potential effect, and this has not been
reported in previous studies which have studied oxytocin/
ergometrine.
Irrespective of our findings, our study will answer the
questions surrounding the use of carbetocin for vaginal
birth and will contribute to the body of evidence comparing
oxytocin and oxytocin/ergometrine. Moreover, this study
will also provide health-related quality of life data, which do
not currently exist for this part of maternity care. This
study has the potential to inform and potentially improve
current clinical practice as well as to optimise the birth
experience of all women giving birth.
Trial status
Authors should report the protocol version number and
date, the date recruitment began and the approximate
date when recruitment will be completed.
Recruitment began in February 2015 and was com-
pleted in August 2018. Protocol version 14 is currently
active. This is illustrated in the IMox SPIRIT figure.
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Additional file 1: SPIRIT checklist for IMox study. (DOCX 24 kb)
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